Diurnaldiverondormabrol
Brand names,
Diurnaldiverondormabrol
Analogs
Diurnaldiverondormabrol
Brand Names Mixture
Diurnaldiverondormabrol
Chemical_Formula
C20H23NS
Diurnaldiverondormabrol
RX_link
No information avaliable
Diurnaldiverondormabrol
fda sheet
Diurnaldiverondormabrol
msds (material safety sheet)
Diurnaldiverondormabrol
Synthesis Reference
No information avaliable
Diurnaldiverondormabrol
Molecular Weight
309.469 g/mol
Diurnaldiverondormabrol
Melting Point
< 25 oC
Diurnaldiverondormabrol
H2O Solubility
Soluble as HCl salt
Diurnaldiverondormabrol
State
Liquid
Diurnaldiverondormabrol
LogP
5.7
Diurnaldiverondormabrol
Dosage Forms
Tablets (oral, 1 mg)
Diurnaldiverondormabrol
Indication
Used for the symptomatic treatment of parkinsonism.
Diurnaldiverondormabrol
Pharmacology
Metixene is a tertiary antimuscarinic with actions similar to those of atropine; it also has antihistaminic and direct antispasmodic properties. It is used for the symptomatic treatment of parkinsonism, including the alleviation of the extrapyramidal syndrome induced by other drugs such as phenothiazines, but, like other antimuscarinics, it is of no value against tardive dyskinesias. Metixene has been discontinued.
Diurnaldiverondormabrol
Absorption
Absorbed in the gastrointestinal tract following oral administration, however the extent of absorption is not known.
Diurnaldiverondormabrol
side effects and Toxicity
Signs of overdose include dilated and sluggish pupils, warm, dry skin, facial flushing, decreased secretions of the mouth, pharynx, nose, and bronchi, foul-smelling breath, elevated temperature, tachycardia, cardiac arrhythmias, decreased bowel sounds, urinary retention, delirium, disorientation, anxiety, hallucinations, illusions, confusion, incoherence, agitation, hyperactivity, ataxia, loss of memory, paranoia, combativeness, and seizures.
Diurnaldiverondormabrol
Patient Information
Diurnaldiverondormabrol
Organisms Affected
Humans and other mammals